ModerateVitamin K antagonist anticoagulants×HIV protease inhibitor / pharmacokinetic booster
Updated · Methodology
Mechanism
Liver enzymes, mainly CYP2C9, metabolise acenocoumarol, and CYP1A2 and CYP2C19 also take part in breaking down its R-enantiomer (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Ritonavir can induce CYP1A2, CYP2C8, CYP2C9 and CYP2C19 and lower the levels of drugs that these enzymes metabolise (ritonavir SmPC, European Medicines Agency, EMA). The acenocoumarol SmPC lists human immunodeficiency virus (HIV) protease inhibitors, including ritonavir, among drugs that can reduce its anticoagulant effect (AEMPS). The documents do not say how much acenocoumarol levels fall. Data exist only for warfarin. Ritonavir 400 mg twice daily reduced the area under the concentration–time curve (AUC) of R-warfarin by 33% and had only a slight effect on S-warfarin (ritonavir SmPC, EMA, and label, US Food and Drug Administration, FDA).
Symptoms
The anticoagulant effect of acenocoumarol can decrease. The international normalised ratio (INR) then falls below the target range, and protection against clots, the reason for acenocoumarol treatment, weakens (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the US ritonavir label, warfarin levels can change in either direction (ritonavir label, US Food and Drug Administration, FDA). After ritonavir is stopped, the effect of acenocoumarol can change again (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS).
Management
The combination is not contraindicated but needs close coagulation monitoring. The acenocoumarol summary of product characteristics (SmPC) lists ritonavir among drugs that can reduce its effect. The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when such a drug is added and when it is stopped (acenocoumarol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The ritonavir documents have no separate entry for acenocoumarol. For warfarin, the European ritonavir SmPC recommends monitoring anticoagulation parameters both at antiretroviral doses of ritonavir and at the low dose used to boost other protease inhibitors. The US ritonavir label recommends frequent international normalised ratio (INR) checks at the start of co-administration (ritonavir SmPC, European Medicines Agency, EMA, and label, US Food and Drug Administration, FDA). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose (acenocoumarol SmPC, AEMPS). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Ficha técnica de Norvir 100 mg comprimidos recubiertos con película (ritonavir) (2026)– AEMPS, CIMA (texto EMA), nº registro 96016005, secciones 4.3 y 4.5
- FDA: Norvir (ritonavir) prescribing information (2026)– AbbVie. NORVIR (ritonavir) tablets, oral solution, oral powder. Prescribing information, DailyMed setid 2849298e-de6e-47bb-8194-56e075b33fc3, sections 4 and 7.2
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.2 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.2 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.2
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 5.2 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 5.2 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 5.2